{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:18:13Z","timestamp":1769167093146,"version":"3.49.0"},"reference-count":146,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Type 2 diabetes (T2D) is associated with diabetic nephropathy as well as nonalcoholic steatohepatitis (NASH), which can be called \u201cdiabetic hepatopathy or diabetic liver disease\u201d. NASH, a severe form of nonalcoholic fatty disease (NAFLD), can sometimes progress to cirrhosis, hepatocellular carcinoma and hepatic failure. T2D patients are at higher risk for liver-related mortality compared with the nondiabetic population. NAFLD is closely associated with chronic kidney disease (CKD) or diabetic nephropathy according to cross-sectional and longitudinal studies. Simultaneous kidney liver transplantation (SKLT) is dramatically increasing in the United States, because NASH-related cirrhosis often complicates end-stage renal disease. Growing evidence suggests that NAFLD and CKD share common pathogenetic mechanisms and potential therapeutic targets. Glucagon-like peptide 1 (GLP-1) receptor agonists and sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors are expected to ameliorate NASH and diabetic nephropathy\/CKD. There are no approved therapies for NASH, but a variety of drug pipelines are now under development. Several agents of them can also ameliorate diabetic nephropathy\/CKD, including peroxisome proliferator-activated receptors agonists, apoptosis signaling kinase 1 inhibitor, nuclear factor-erythroid-2-related factor 2 activator, C-C chemokine receptor types 2\/5 antagonist and nonsteroidal mineral corticoid receptor antagonist. This review focuses on common drug pipelines in the treatment of diabetic nephropathy and hepatopathy.<\/jats:p>","DOI":"10.3390\/ijms21144939","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T09:30:49Z","timestamp":1594719049000},"page":"4939","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-1361","authenticated-orcid":false,"given":"Yoshio","family":"Sumida","sequence":"first","affiliation":[{"name":"Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi 480-1195, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi 480-1195, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-6168","authenticated-orcid":false,"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0976-6761","authenticated-orcid":false,"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Himeji Redcross Hospital, Himeji, Hyogo 670-8540, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu Municipal Hospital, Gifu 500-8513, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Nishigaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu Municipal Hospital, Gifu 500-8513, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu Municipal Hospital, Gifu 500-8513, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Naiki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu Municipal Hospital, Gifu 500-8513, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0760-3045","authenticated-orcid":false,"given":"Asahiro","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2408-2023","authenticated-orcid":false,"given":"Hiroshi","family":"Tobita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Izumo, Shimane 693-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Izumo City General Medical Center, Izumo, Shimane 691-0003, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Kawabe","sequence":"additional","affiliation":[{"name":"Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University School of Medicine, Aichi 470-1192, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Fukunishi","sequence":"additional","affiliation":[{"name":"Premier Development Research of Medicine, Osaka Medical College, Osaka 569-8686, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9216-3186","authenticated-orcid":false,"given":"Tadashi","family":"Ikegami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center, Ibaraki 300-0395, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaomi","family":"Kessoku","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yohokama, Kanagawa 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yohokama, Kanagawa 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1624-5462","authenticated-orcid":false,"given":"Yasushi","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yohokama, Kanagawa 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Munekage","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi 780-8505, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunehiro","family":"Ochi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi 780-8505, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hematology\/Oncology, Asahikawa Medical University, Asahikawa 078-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taeang","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo 113-8602, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Kogiso","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Gastroenterology, Tokyo Women\u2019s Medical University, Tokyo 162-8266, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kimoto","sequence":"additional","affiliation":[{"name":"Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi 480-1195, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Notsumata","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Fukui-ken Saiseikai Hospital, Fukui 918-8503, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Nonaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, JA Hiroshima General Hospital, Hiroshima 738-8503, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4986-8578","authenticated-orcid":false,"given":"Kazuhito","family":"Kawata","sequence":"additional","affiliation":[{"name":"Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6689-4989","authenticated-orcid":false,"given":"Taro","family":"Takami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kumada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2836-0414","authenticated-orcid":false,"given":"Eiichi","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu Municipal Hospital, Gifu 500-8513, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-3400","authenticated-orcid":false,"given":"Takeshi","family":"Okanoue","sequence":"additional","affiliation":[{"name":"Hepatology Center, Saiseikai Suita Hospital, Suita, Osaka 564-0013, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6263-1436","authenticated-orcid":false,"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yohokama, Kanagawa 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Japan Study Group of NAFLD (JSG-NAFLD)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00535-012-0533-z","article-title":"Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: A multicenter large retrospective study","volume":"47","author":"Eguchi","year":"2012","journal-title":"J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","article-title":"Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation","volume":"152","author":"Goldberg","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jdi.12645","article-title":"Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001\u20132010: Report of the Committee on Causes of Death in Diabetes Mellitus","volume":"8","author":"Nakamura","year":"2017","journal-title":"J. Diabetes Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00535-018-1494-7","article-title":"Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients","volume":"54","author":"Shima","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1007\/s00125-017-4229-z","article-title":"Association between type 2 diabetes and risk of cancer mortality: A pooled analysis of over 771,000 individuals in the Asia Cohort Consortium","volume":"60","author":"Chen","year":"2017","journal-title":"Diabetologia"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sumida, Y., Shima, T., Mitsumoto, Y., Katayama, T., Umemura, A., Yamaguchi, K., Itoh, Y., Yoneda, M., and Okanoue, T. (2020). Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124337"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"ref_9","first-page":"287","article-title":"Japan Study Group of NAFLD (JSG-NAFLD). Estimated Prevalence of Advanced Hepatic Fibrosis by Elastography in Patients with Type 2 Diabetes","volume":"3","author":"Sumida","year":"2020","journal-title":"Interv. Obes. Diabetes"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/TP.0000000000000945","article-title":"Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States","volume":"100","author":"Singal","year":"2016","journal-title":"Transplantation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep4.1408","article-title":"Nonalcoholic Fatty Liver Disease and Renal Function Impairment: A Cross-Sectional Population-Based Study on Its Relationship from 1999 to 2016","volume":"3","author":"Le","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/TP.0000000000000048","article-title":"Evolving Frequency and Outcomes of Simultaneous Liver Kidney Transplants Based on Liver Disease Etiology","volume":"98","author":"Singal","year":"2014","journal-title":"Transplantation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/MEG.0000000000001169","article-title":"Nonalcoholic fatty liver disease and albuminuria","volume":"30","author":"Wijarnpreecha","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jhep.2017.09.020","article-title":"Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes","volume":"68","author":"Yeung","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.metabol.2010.07.022","article-title":"Nonalcoholic steatohepatitis and increased risk of chronic kidney disease","volume":"60","author":"Yasui","year":"2011","journal-title":"Metabolism"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Musso, G., Gambino, R., Tabibian, J.H., Ekstedt, M., Kechagias, S., Hamaguchi, M., Hultcrantz, R., Hagstr\u00f6m, H., Yoon, S.K., and Charatcharoenwitthaya, P. (2014). Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. PLoS Med., 11.","DOI":"10.1371\/journal.pmed.1001680"},{"key":"ref_18","first-page":"2205","article-title":"In female patients with non-alcoholic fatty liver disease (NAFLD) presence, of type 2 diabetes (DM) and chronic kidney disease (CKD) are independently associated with the risk of mortality","volume":"62","author":"Stepanova","year":"2015","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000355808","article-title":"Nonalcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Risk in Renal Transplant Recipients","volume":"39","author":"Mikolasevic","year":"2014","journal-title":"Kidney Blood Press. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jhep.2017.08.024","article-title":"Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study","volume":"67","author":"Sinn","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Seko, Y., Yano, K., Takahashi, A., Okishio, S., Kataoka, S., Okuda, K., Mizuno, N., Takemura, M., Taketani, H., and Umemura, A. (2019). FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010171"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/liv.14419","article-title":"PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings","volume":"40","author":"Mantovani","year":"2020","journal-title":"Liver Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1038\/s41598-018-23014-0","article-title":"Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: A cohort study","volume":"8","author":"Jang","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Marcuccilli, M., and Chonchol, M. (2016). NAFLD and Chronic Kidney Disease. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17040562"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/978-981-13-8871-2_19","article-title":"Role of Inflammasome in Chronic Kidney Disease","volume":"1165","author":"Li","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/hepr.12883","article-title":"Hepatic nucleotide binding oligomerization domain-like receptors pyrin domain-containing 3 inflammasomes are associated with the histologic severity of non-alcoholic fatty liver disease","volume":"47","author":"Mitsuyoshi","year":"2017","journal-title":"Hepatol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6489012","DOI":"10.1155\/2016\/6489012","article-title":"Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH","volume":"2016","author":"Wan","year":"2016","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.cgh.2016.08.002","article-title":"New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis\u2013Related Kidney Disease","volume":"15","author":"Musso","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/hepr.13425","article-title":"Japan Study Group of NAFLD (JSG-NAFLD) Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis","volume":"49","author":"Sumida","year":"2019","journal-title":"Hepatol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Wang, Y., Nakajima, T., Gonzalez, F.J., and Tanaka, N. (2020). PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062061"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biochi.2016.11.009","article-title":"PPARs and nonalcoholic fatty liver disease","volume":"136","author":"Liss","year":"2017","journal-title":"Biochimie"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to Pioglitazone in Patients with Nonalcoholic Steatohepatitis With vs. Without Type 2 Diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1111\/j.1440-1797.2005.00456.x","article-title":"Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases","volume":"10","author":"Chung","year":"2005","journal-title":"Nephrology (Carlton)"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ihj.2015.02.007","article-title":"Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients","volume":"67","author":"Shetty","year":"2015","journal-title":"Indian Heart J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist\u2014Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: Integrated analysis of the real world evidence","volume":"18","author":"Kaul","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.2337\/dc13-2480","article-title":"Can a selective PPAR\u03b3 modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?","volume":"37","author":"DePaoli","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_42","unstructured":"Gawrieh, S. (2019). A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients with Nonalcoholic Fatty Liver Disease and\/or Nonalcoholic Steatohepatitis (Evidences IV), AASLD. #LO10."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ruilope, L.M., Hanefeld, M., Lincoff, A.M., Viberti, G., Meyer-Reigner, S., Mudie, N., Kirk, D.W., Malmberg, K., and Herz, M. (2014). Effects of the dual peroxisome proliferator-activated receptor-\u03b1\/\u03b3 agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: A Phase IIb, randomized study. BMC Nephrol., 15.","DOI":"10.1186\/1471-2369-15-180"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6740616","DOI":"10.1155\/2019\/6740616","article-title":"Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice","volume":"2019","author":"Tsai","year":"2019","journal-title":"BioMed Res. Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8157","DOI":"10.1038\/s41598-018-26383-8","article-title":"Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis","volume":"8","author":"Goto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejphar.2018.09.009","article-title":"Farnesoid X receptoragonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury","volume":"838","author":"Zhu","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1681\/ASN.2017020222","article-title":"FXR\/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity","volume":"29","author":"Wang","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"F1587","DOI":"10.1152\/ajprenal.00404.2009","article-title":"Thefarnesoid X receptor modulates renal lipid metabolism and diet-inducedrenal inflammation, fibrosis, and proteinuria","volume":"297","author":"Wang","year":"2009","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000341485","article-title":"Effect of Chenodeoxycholic Acid on Fibrosis, Inflammation and Oxidative Stress in Kidney in High-Fructose-Fed Wistar Rats","volume":"36","author":"Hu","year":"2012","journal-title":"Kidney Blood Press. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1074\/jbc.M115.694323","article-title":"Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice","volume":"291","author":"Gai","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3109\/10715762.2013.837577","article-title":"Involvement of free radicals and oxidative stress in NAFLD\/NASH","volume":"47","author":"Sumida","year":"2013","journal-title":"Free Radic. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/847539","article-title":"Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease\u2014Is There a Link?","volume":"2014","author":"Orlic","year":"2014","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Vomund, S., Sch\u00e4fer, A., Parnham, M.J., Br\u00fcne, B., and Von Knethen, A. (2017). Nrf2, the Master Regulator of Anti-Oxidative Responses. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122772"},{"key":"ref_55","first-page":"161","article-title":"The Effects of Oltipraz on Tissue Regeneration in the Process of Wound Healing: A Stereological Study","volume":"2","author":"Noorafshan","year":"2014","journal-title":"Bull. Emerg. Trauma"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/apt.13981","article-title":"Randomised clinical trial: The efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease","volume":"45","author":"Kim","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1590\/s1677-5538.ibju.2018.0232","article-title":"Beneficial effects of Oltipraz, nuclear factor-erythroid\u20132-related factor 2 (Nrf2), on renal damage in unilateral ureteral obstruction rat model","volume":"44","author":"Polat","year":"2018","journal-title":"Int. Braz. J. Urol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1073\/pnas.0500815102","article-title":"Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress","volume":"102","author":"Liby","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1535-7163.MCT-06-0516","article-title":"Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes","volume":"6","author":"Yates","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/np100826q","article-title":"ChemInform Abstract: New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress","volume":"42","author":"Sporn","year":"2011","journal-title":"J. Nat. Prod."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1152\/physrev.00023.2017","article-title":"The KEAP1-NRF2 System: A Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis","volume":"98","author":"Yamamoto","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"Akizawa","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000346948","article-title":"Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)","volume":"37","author":"Akizawa","year":"2013","journal-title":"Am. J. Nephrol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ekir.2020.03.030","article-title":"Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)","volume":"5","author":"Nangaku","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.mce.2015.05.018","article-title":"Bardoxolone methyl prevents insulin resistance and the development of hepatic steatosis in mice fed a high-fat diet","volume":"412","author":"Camer","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"6","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","article-title":"Roles for Chemokines in Liver Disease","volume":"147","author":"Marra","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/dom.12309","article-title":"CCR2 antagonism in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study","volume":"16","author":"Artis","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/13543784.2018.1442436","article-title":"Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis","volume":"27","author":"Tacke","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Lefebvre, E., Moyle, G., and Reshef, R. (2016). Antifibrotic Effects of the Dual CCR2\/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158156"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Ratziu, V., Sanyal, A., Harrison, S.A., Wong, V.W., Francque, S., Goodman, Z., Aithal, G.P., Kowdley, K.V., Seyedkazemi, S., and Fischer, L. (2020). Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology, in press.","DOI":"10.1002\/hep.31108"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"105922","DOI":"10.1016\/j.cct.2019.105922","article-title":"Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design","volume":"89","author":"Anstee","year":"2019","journal-title":"Contemp. Clin. Trials"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: A randomised trial","volume":"3","author":"Bekker","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ekir.2018.07.010","article-title":"Effect of PF-04634817, an Oral CCR2\/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy","volume":"3","author":"Gale","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2013.03.033","article-title":"Decoding cell death signals in liver inflammation","volume":"59","author":"Brenner","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrgastro.2017.42","article-title":"Novel therapeutic strategies targeting ASK1 in NASH","volume":"14","author":"Schuster","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41581-018-0063-x","article-title":"ASK1 inhibition shows potential in DKD","volume":"14","author":"Kelsey","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2337\/db15-0384","article-title":"ASK1 Inhibitor Halts Progression of Diabetic Nephropathy inNos3-Deficient Mice","volume":"64","author":"Tesch","year":"2015","journal-title":"Diabetes"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1681\/ASN.2018121231","article-title":"Effects of Selonsertib in Patients with Diabetic Kidney Disease","volume":"30","author":"Chertow","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.4049\/jimmunol.180.4.2650","article-title":"Regulation of alternative macrophage activation by galectin-3","volume":"180","author":"MacKinnon","year":"2008","journal-title":"J. Immunol."},{"key":"ref_84","first-page":"599","article-title":"Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)","volume":"41","author":"Dong","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Traber, P.G., and Zomer, E. (2013). Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083481"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Chen, S.-C., and Kuo, P.-L. (2016). The Role of Galectin-3 in the Kidneys. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17040565"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-065X.2009.00794.x","article-title":"The regulation of inflammation by galectin-3","volume":"230","author":"Henderson","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/apt.13816","article-title":"Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","volume":"44","author":"Harrison","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_89","first-page":"1334","article-title":"Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension","volume":"15","author":"Chalasani","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s11255-019-02123-3","article-title":"Prognostic impact of galectin-3 in chronic kidney disease patients: A systematic review and meta-analysis","volume":"51","author":"Zhang","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2147\/DMSO.S194410","article-title":"Galectin-3 as a prognostic biomarker for diabetic nephropathy","volume":"12","author":"Hodeib","year":"2019","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Li, H., Yang, S., Li, J.-C., and Feng, J.-X. (2018). Galectin 3 inhibition attenuates renal injury progression in cisplatin-induced nephrotoxicity. Biosci. Rep., 38.","DOI":"10.1042\/BSR20181803"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1681\/ASN.V34s97","article-title":"A controlled clinical trial ofangiotensin-converting enzyme inhibition in type I diabetic nephropathy: Study design and patient characteristics. The Collaborative Study Group","volume":"3","author":"Bain","year":"1992","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/hep.20420","article-title":"Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis","volume":"40","author":"Yokohama","year":"2004","journal-title":"Hepatology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"587140","DOI":"10.1155\/2013\/587140","article-title":"Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)","volume":"2013","author":"Hirata","year":"2013","journal-title":"Int. J. Endocrinol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"24155","DOI":"10.18632\/oncotarget.23816","article-title":"Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"9","author":"Li","year":"2018","journal-title":"Oncotarget"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40620-019-00600-7","article-title":"New mineralocorticoid receptor antagonists: Update on their use in chronic kidney disease and heart failure","volume":"33","author":"Capelli","year":"2020","journal-title":"J. Nephrol."},{"key":"ref_98","first-page":"407","article-title":"Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats","volume":"26","author":"Yoshiji","year":"2010","journal-title":"Int. J. Mol. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1111\/liv.12794","article-title":"Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis","volume":"35","author":"Pizarro","year":"2015","journal-title":"Liver Int."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-981-13-8871-2_15","article-title":"Role of Aldosterone in Renal Fibrosis","volume":"1165","author":"Shrestha","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1254\/jphs.10R07CR","article-title":"Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney","volume":"115","author":"Rafiq","year":"2011","journal-title":"J. Pharmacol. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","article-title":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs","volume":"93","author":"Georgianos","year":"2017","journal-title":"Kidney Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J. Endocrinol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/BF01316798","article-title":"Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man","volume":"38","author":"Schjoldager","year":"1993","journal-title":"Dig. Dis. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3748\/wjg.v22.i8.2512","article-title":"Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice","volume":"22","author":"Yamamoto","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-\/- and LDLr-\/- Mice by a Mechanism That Includes Inflammatory Pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_109","first-page":"1","article-title":"Nephroprotective effects of GLP-1 receptor agonists: Where do we stand?","volume":"10","author":"Mosterd","year":"2020","journal-title":"J. Nephrol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41581-018-0055-x","article-title":"Renoprotective effects of dulaglutide in patients with T2DM and CKD","volume":"14","author":"Sorensen","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Greco, E.V., Russo, G.T., Giandalia, A., Viazzi, F., Pontremoli, R., and De Cosmo, S. (2019). GLP-1 Receptor Agonists and Kidney Protection. Medicina, 55.","DOI":"10.3390\/medicina55060233"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Sumida, Y., Yoneda, M., Tokushige, K., Kawanaka, M., Fujii, H., Yoneda, M., Imajo, K., Takahashi, H., Eguchi, Y., and Ono, M. (2020). Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Int. J. Mol. Sci., 21.","DOI":"10.20944\/preprints202001.0171.v1"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/hepr.12834","article-title":"Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus","volume":"47","author":"Seko","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Komiya, C., Tsuchiya, K., Shiba, K., Miyachi, Y., Furuke, S., Shimazu, N., Yamaguchi, S., Kanno, K., and Ogawa, Y. (2016). Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151511"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1507\/endocrj.EJ16-0295","article-title":"Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: An association with glucose-lowering effects","volume":"64","author":"Takase","year":"2017","journal-title":"Endocr. J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.2169\/internalmedicine.8754-16","article-title":"The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin","volume":"56","author":"Takeda","year":"2017","journal-title":"Intern. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep4.1019","article-title":"Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies","volume":"1","author":"Akuta","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2147\/DMSO.S184767","article-title":"Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1\u20133 fibrosis","volume":"11","author":"Seko","year":"2018","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/dom.13061","article-title":"Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study","volume":"20","author":"Shibuya","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hepr.13236","article-title":"Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with NAFLD: A prospective, single arm trial","volume":"49","author":"Sumida","year":"2019","journal-title":"Hepatol. Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.2337\/dc15-1182","article-title":"Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities","volume":"39","author":"Musso","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"104617","DOI":"10.1016\/j.phrs.2019.104617","article-title":"The gut-liver-kidney axis: Novel regulator of fatty liver associated chronic kidney disease","volume":"152","author":"Raj","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cct.2018.05.010","article-title":"Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease","volume":"71","author":"Scorletti","year":"2018","journal-title":"Contemp. Clin. Trials"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients with Non-alcoholic Fatty Liver Disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1484598","DOI":"10.1155\/2019\/1484598","article-title":"Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease","volume":"2019","author":"Xiao","year":"2019","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s12325-010-0059-9","article-title":"Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease","volume":"27","author":"Ranganathan","year":"2010","journal-title":"Adv. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Rossi, M., Johnson, D.W., Morrison, M., Pascoe, E.M., Coombes, J.S., Forbes, J.M., McWhinney, B., Ungerer, J., Dimeski, G., and Campbell, K.L. (2014). SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): A protocol of placebo-controlled randomised cross-over trial. BMC Nephrol., 15.","DOI":"10.1186\/1471-2369-15-106"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/673631","article-title":"Pre-, Pro-, and Synbiotics: Do They Have a Role in Reducing Uremic Toxins? A Systematic Review and Meta-Analysis","volume":"2012","author":"Rossi","year":"2012","journal-title":"Int. J. Nephrol."},{"key":"ref_142","first-page":"664","article-title":"Glucagon-like peptide-1 (GLP-1): Effect on kidney hemodynamics and renin\u2013angiotensin\u2013aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"Endocr. Abstr."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000337929","article-title":"Exenatide Reduces Urinary Transforming Growth Factor-\u00df1 and Type IV Collagen Excretion in Patients with Type 2 Diabetes and Microalbuminuria","volume":"35","author":"Zhang","year":"2012","journal-title":"Kidney Blood Press. Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1681\/ASN.2018010103","article-title":"Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial","volume":"29","author":"Wanner","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"17","DOI":"10.36502\/2020\/droa.6159","article-title":"Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease","volume":"2","author":"Sumida","year":"2020","journal-title":"Diabetes Res. Open Access"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/14\/4939\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:50:47Z","timestamp":1760176247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/14\/4939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":146,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["ijms21144939"],"URL":"https:\/\/doi.org\/10.3390\/ijms21144939","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]}}}